Debt-to-equity of Vera Therapeutics, Inc. from 30 Sep 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vera Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2021 to 30 Sep 2025.
  • Vera Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 19%, a 28% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Vera Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 19% -8% -28% 30 Sep 2025
Q2 2025 18% -10% -36% 30 Jun 2025
Q1 2025 18% -17% -49% 31 Mar 2025
Q4 2024 19% -25% -57% 31 Dec 2024
Q3 2024 27% -16% -37% 30 Sep 2024
Q2 2024 29% -10% -26% 30 Jun 2024
Q1 2024 34% 0% -0.81% 31 Mar 2024
Q4 2023 44% +13% +41% 31 Dec 2023
Q3 2023 43% +20% +89% 30 Sep 2023
Q2 2023 39% +20% +105% 30 Jun 2023
Q1 2023 35% +20% +136% 31 Mar 2023
Q4 2022 31% +11% +57% 31 Dec 2022
Q3 2022 23% +441% 30 Sep 2022
Q2 2022 19% 30 Jun 2022
Q1 2022 15% 31 Mar 2022
Q4 2021 20% 31 Dec 2021
Q3 2021 -419% 30 Sep 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.